Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
Launched by UNIVERSITY OF CHICAGO · Apr 1, 2019
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways of helping patients breathe when they are on a machine called a ventilator. The goal is to see how these methods, known as controlled mode ventilation and support mode ventilation, affect how long patients can breathe on their own after being on the ventilator and whether they experience a condition called diaphragmatic atrophy, which is when the diaphragm muscle weakens from not being used enough.
To be part of this study, participants need to be at least 18 years old and have been on a ventilator for less than 36 hours. However, certain people are not eligible, including those who are pregnant, have had a recent lung emergency, or have specific muscle or nerve issues. If you join the trial, you will receive one of the two breathing support methods, and the research team will monitor your recovery process closely. This study is currently looking for participants, so if you or your family member might qualify, it could be a valuable opportunity to contribute to important medical research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subjects \> 18 years of age that have been intubated and mechanically ventilated for \< 36 hours at the time of screening will be eligible for enrollment
- Exclusion Criteria:
- • 1. pregnancy
- • 2. cardiopulmonary arrest
- • 3. history of diaphragmatic paralysis or neuromuscular disease
- • 4. chronic obstructive pulmonary disease (COPD) or asthma exacerbation with evidence of auto-PEEPing requiring intubation
- • 5. neuromuscular blockade
- • 6. expectation to be liberated from ventilator in \< 24 hours
- • 7. history of mechanical ventilation in the last 6 months
- • 8. presence of tracheostomy
- • 9. high cervical spine injury
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Chicago, Illinois, United States
Patients applied
Trial Officials
John P Kress, MD
Study Director
University of Chicago
Bhakti Patel, MD
Principal Investigator
University of Chicago
Roger Struble, MD
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials